Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. (Nasdaq: GANX) is a clinical-stage biotechnology company whose news flow is closely tied to the development of its lead drug candidate, GT-02287, and to progress in its broader allosteric small molecule pipeline. The company focuses on next generation allosteric therapies targeting neurodegenerative diseases, rare genetic disorders and oncology, with a primary emphasis on Parkinson’s disease.
News about Gain Therapeutics frequently covers clinical milestones for GT-02287, including updates from its Phase 1 and Phase 1b studies in people with Parkinson’s disease with or without a GBA1 mutation. Press releases have detailed safety and tolerability findings, exploratory biomarker data such as reductions in glucosylsphingosine (GluSph) in cerebrospinal fluid, and observations related to Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) scores. These items provide insight into how the company interprets GT-02287’s potential disease-modifying effects and mechanism of action.
Investors and observers can also expect regular announcements on preclinical research and scientific presentations. Gain Therapeutics reports data from preclinical models that explore GCase modulation, mitochondrial and lysosomal health, and neuroprotection in Parkinson’s disease. Poster presentations at scientific meetings, such as Neuroscience conferences and Parkinson’s-focused congresses, are common subjects of the company’s news releases.
Additional news items include corporate updates and financial disclosures, such as quarterly financial results, capital raises, changes in board composition, and shareholder meeting outcomes. The company also issues notices about participation in investor conferences, key opinion leader (KOL) events, and webinars that discuss biomarkers, clinical endpoints and emerging data from GT-02287 studies.
For readers following GANX, the news page provides a centralized view of clinical trial progress, scientific data, regulatory and corporate developments, and event participation related to Gain Therapeutics’ efforts in allosteric small molecule drug development.
Gain Therapeutics (Nasdaq: GANX) reported Q3 2025 results and clinical updates for lead candidate GT-02287.
Highlights: completed enrollment of 21 participants in the Phase 1b Parkinson’s study (target 15), presented initial data showing MDS‑UPDRS stabilization/improvement after ~30–90 days, no treatment‑emergent serious adverse events, plasma PK within projected therapeutic range, and Australian approval to extend dosing to a total of 12 months. Analysis of functional changes and biomarkers at Day 90 is expected in Q4 2025. Company reported $8.8M cash at Sept 30, 2025, and completed a public offering netting approximately $7.1M.
Gain Therapeutics (Nasdaq: GANX) will present a poster at Neuroscience 2025 in San Diego, taking place November 15–19, 2025.
The poster (Session: Poster PSTR438) is titled “GT-02287, a small molecule allosteric modulator of lysosomal enzyme glucocerebrosidase (GCase), acts at both lysosomes and mitochondria”. Presentation is scheduled for Wednesday, November 19, 2025, 1:00 PM–5:00 PM in SDCC Halls B-H. The topic focuses on developing Parkinson’s disease therapeutic strategies using cellular models.
Gain Therapeutics (Nasdaq: GANX) will participate in the 2025 Maxim Growth Summit on October 22–23, 2025 at The Hard Rock Hotel NYC.
Gene Mack, President and CEO, will join a live discussion on October 22 titled “Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutics Categories.” The panel will cover innovative approaches for neurodegenerative diseases that are currently in active clinical trials. Investors or analysts interested in a meeting with Gain management are instructed to contact their Maxim sales representative to schedule.
Gain Therapeutics (NASDAQ: GANX) will host a virtual Key Opinion Leader event titled “Biomarkers, Clinical Endpoints, and the Path to Disease Modification: Contextualizing the emerging data from GT-02287” on October 14, 2025 at 4:00 p.m. EST.
Speakers include Karl Kieburtz, M.D., M.P.H., and Kenneth Marek, M.D. Presentations will review biomarkers, clinical outcome scales, and endpoints to contextualize Phase 1b data for GT-02287 in Parkinson’s disease. The Phase 1b data presented show GT-02287 was generally well tolerated with no treatment-emergent serious adverse events and trending improvements in MDS-UPDRS scores. A live Q&A will follow the presentations.
Gain Therapeutics (NASDAQ: GANX) presented interim Phase 1b data for GT-02287 in Parkinson’s disease on October 6, 2025. Early dosing produced stability and trending improvements in MDS‑UPDRS Parts II and III by Day 90 in several participants while Part I remained unchanged.
GT-02287 was generally well tolerated with no treatment‑emergent serious adverse events, a consistent plasma PK profile within the projected therapeutic range, and DMC recommendations to continue the study. Australian authorities approved a study extension allowing treatment up to 12 months. A virtual KOL webinar is scheduled for October 14, 2025.
Gain Therapeutics (NASDAQ:GANX), a clinical-stage biotech company focused on developing next-generation allosteric small-molecule therapies, announced its participation in the Drug Discovery Innovation Programme 2025. Dr. Rinaldo Montalvão, the company's Director of Artificial Intelligence, will present a talk titled "Transforming Drug Discovery: Generative Models and Electrostatic Complementarity" during the AI and Automation in Drug Discovery track on September 26, 2025, at 9:20am CEST in Barcelona, Spain.
Gain Therapeutics (NASDAQ:GANX) has initiated a Phase 1b extension study for its Parkinson's disease treatment GT-02287, allowing participants to continue dosing for an additional nine months beyond the initial 90-day schedule. The original Phase 1b study, which enrolled 21 participants, is set to complete in December 2025.
The company will present early results from the Phase 1b study at the International Congress of Parkinson's Disease and Movement Disorders on October 7, 2025. Additional data, including MDS-UPDRS functional changes and biomarker data from cerebrospinal fluid and blood, will be available in Q4 2025. Management reports encouraging early observations regarding safety, tolerability, pharmacokinetics, and functional impact.
Gain Therapeutics (Nasdaq: GANX) has received approval from Australian authorities to extend the dosing period in its Phase 1b clinical trial of GT-02287 by an additional nine months. The extension allows participants who completed the initial 90-day treatment period to continue for up to 12 months total.
Additionally, the independent Data Monitoring Committee (DMC) has recommended continuing the study without modifications after reviewing interim safety data, finding no safety concerns. The majority of participants who completed the initial 90-day period have expressed interest in joining the extension phase.
The extended study will assess long-term safety, tolerability, functional changes according to the Movement Disorder Society Unified Parkinson's Disease Rating Scale, and biomarker activity from cerebrospinal fluid, with data intended to support Phase 2 planning.
Gain Therapeutics (NASDAQ:GANX) has reported significant progress in its Phase 1b study of GT-02287 for Parkinson's Disease. The company achieved full enrollment earlier than expected, with 16 patients enrolled as of June 30, 2025, and total enrollment not expected to exceed 20 participants.
Key financial updates include a successful public offering raising $7.1 million in net proceeds and reduced operational expenses, with R&D expenses decreasing to $2.8 million from $4.4 million year-over-year. The company's net loss improved to $0.19 per share from $0.42 per share in the previous year.
Important upcoming milestones include analysis of functional changes and biomarker activity expected in Q4 2025, potential extension of the dosing duration beyond 90 days, and an FDA IND submission planned by year-end 2025.
Gain Therapeutics (NASDAQ:GANX), a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies, will participate in BTIG's Annual Virtual Biotechnology Conference on July 29-30, 2025.
The company's management team will engage in a fireside chat on Wednesday, July 30, 2025, at 3:20 PM ET. Additionally, they will be available for one-on-one meetings with registered conference attendees through BTIG banking representatives.